| Dr Jacqueline Haydee Hunterton-anderson, DNP, PMHNP-BC | |
|
280 Newton Sparta Rd Ste 2, Newton, NJ 07860-2775 | |
| (973) 903-7161 | |
| (973) 860-1152 |
| Full Name | Dr Jacqueline Haydee Hunterton-anderson |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 280 Newton Sparta Rd Ste 2, Newton, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710597422 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Middlesex Psychiatry And Tms Pc | 7315334000 | 21 |
News Archive
Australian cancer researchers will gain access to first-in-Australia technology through new funding from Australian Cancer Research Foundation to the Walter and Eliza Hall Institute. The $2.5 million grant will allow the establishment of the ACRF Breakthrough Technologies Laboratory, providing new insights into how cancer develops, and how it can be more effectively treated. The laboratory is one of four initiatives announced by ACRF last night.
A new mobile radiology application cleared today by the U.S. Food and Drug Administration will allow physicians to view medical images on the iPhone and iPad manufactured by Apple Inc.
A new study conducted by the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital found that from 1997-2007, an estimated 229,023 children and adolescents younger than 19 years were treated in U.S. hospital emergency departments for sledding-related injuries, an average of more than 20,000 cases each year.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
As childhood obesity continues its thirty-year advance from occasional curiosity to cultural epidemic, health care providers are struggling to find out why-and the reasons are many. Increasingly sedentary environments for both adults and children, as well as cheap and ubiquitous processed foods no doubt play a role, but researchers are finding more evidence that the first clues for childhood obesity may begin as far back as early infancy.
› Verified 6 days ago
| Entity Name | Middlesex Psychiatry & Tms Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053971572 PECOS PAC ID: 7315334000 Enrollment ID: O20220427002709 |
News Archive
Australian cancer researchers will gain access to first-in-Australia technology through new funding from Australian Cancer Research Foundation to the Walter and Eliza Hall Institute. The $2.5 million grant will allow the establishment of the ACRF Breakthrough Technologies Laboratory, providing new insights into how cancer develops, and how it can be more effectively treated. The laboratory is one of four initiatives announced by ACRF last night.
A new mobile radiology application cleared today by the U.S. Food and Drug Administration will allow physicians to view medical images on the iPhone and iPad manufactured by Apple Inc.
A new study conducted by the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital found that from 1997-2007, an estimated 229,023 children and adolescents younger than 19 years were treated in U.S. hospital emergency departments for sledding-related injuries, an average of more than 20,000 cases each year.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
As childhood obesity continues its thirty-year advance from occasional curiosity to cultural epidemic, health care providers are struggling to find out why-and the reasons are many. Increasingly sedentary environments for both adults and children, as well as cheap and ubiquitous processed foods no doubt play a role, but researchers are finding more evidence that the first clues for childhood obesity may begin as far back as early infancy.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jacqueline Haydee Hunterton-anderson, DNP, PMHNP-BC 280 Newton Sparta Rd Ste 2, Newton, NJ 07860-2775 Ph: (973) 903-7161 | Dr Jacqueline Haydee Hunterton-anderson, DNP, PMHNP-BC 280 Newton Sparta Rd Ste 2, Newton, NJ 07860-2775 Ph: (973) 903-7161 |
News Archive
Australian cancer researchers will gain access to first-in-Australia technology through new funding from Australian Cancer Research Foundation to the Walter and Eliza Hall Institute. The $2.5 million grant will allow the establishment of the ACRF Breakthrough Technologies Laboratory, providing new insights into how cancer develops, and how it can be more effectively treated. The laboratory is one of four initiatives announced by ACRF last night.
A new mobile radiology application cleared today by the U.S. Food and Drug Administration will allow physicians to view medical images on the iPhone and iPad manufactured by Apple Inc.
A new study conducted by the Center for Injury Research and Policy of The Research Institute at Nationwide Children's Hospital found that from 1997-2007, an estimated 229,023 children and adolescents younger than 19 years were treated in U.S. hospital emergency departments for sledding-related injuries, an average of more than 20,000 cases each year.
Sanofi-aventis announced today that the U.S. Food and Drug Administration (FDA) has approved Multaq (dronedarone) 400 mg Tablets. Patients with atrial fibrillation (AF) or atrial flutter (AFL) soon will have a new treatment option to help improve current management of their disease. Multaq is the first drug approved in the United States that has shown a clinical benefit to reduce cardiovascular hospitalization in patients with AF/AFL.
As childhood obesity continues its thirty-year advance from occasional curiosity to cultural epidemic, health care providers are struggling to find out why-and the reasons are many. Increasingly sedentary environments for both adults and children, as well as cheap and ubiquitous processed foods no doubt play a role, but researchers are finding more evidence that the first clues for childhood obesity may begin as far back as early infancy.
› Verified 6 days ago
Ms. Lori Bravenboer, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 181 High St, Newton, NJ 07860 Phone: 973-383-9898 | |
Maria L Bazsa, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 222 High St, Suite 205, Newton, NJ 07860 Phone: 973-579-2100 Fax: 973-579-6638 | |
Mrs. Leatrice M Current, APN-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 33 Newton Sparta Rd Ste 1, Newton, NJ 07860 Phone: 973-383-2244 Fax: 973-383-0448 | |
Mrs. Tara Constantino, FNP-BC Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 181 High St, Newton, NJ 07860 Phone: 973-383-9898 | |
Theresa Papagna, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 175 High St, Newton, NJ 07860 Phone: 973-579-8541 | |
Mr. Elizalde Legarda Villaruz, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1 Slate Hill Rd, Newton, NJ 07860 Phone: 973-383-8865 | |
Kayla Kathleen Poalillo, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 12 Lawrence Rd, Newton, NJ 07860 Phone: 973-948-7595 |